NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions.
The fund generally is expected to consist of more than 15 companies but not more than 100 companies.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 10.16% |
| UNH | UnitedHealth Group Incorporated | Healthcare | Healthcare Plans | 6.10% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.16% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.12% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Biotechnology | 3.94% |
| 0QIU | Novo Nordisk A/S Class B | 3.92% | ||
| ABT | Abbott Laboratories | Healthcare | Medical Devices | 3.86% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 3.85% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 3.36% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 3.12% |
| TMO | Thermo Fisher Scientific Inc | Healthcare | Diagnostics & Research | 3.06% |
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 3.06% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 3.05% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 2.91% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.70% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.61% |
| CRNX | Crinetics Pharmaceuticals Inc | Healthcare | Biotechnology | 2.56% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.44% |
| CYTK | Cytokinetics Inc | Healthcare | Biotechnology | 2.18% |
| DHR | Danaher Corporation | Healthcare | Diagnostics & Research | 2.04% |